These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 20443871)

  • 1. Induction of antitumor immunity by semi-allogeneic and fully allogeneic electrofusion products of tumor cells and dendritic cells.
    Siders WM; Garron C; Shields J; Kaplan JM
    Clin Transl Sci; 2009 Feb; 2(1):75-9. PubMed ID: 20443871
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction of specific antitumor immunity in the mouse with the electrofusion product of tumor cells and dendritic cells.
    Siders WM; Vergilis KL; Johnson C; Shields J; Kaplan JM
    Mol Ther; 2003 Apr; 7(4):498-505. PubMed ID: 12727113
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Allogeneic tumor vaccine produced by electrofusion between osteosarcoma cell line and dendritic cells in the induction of antitumor immunity.
    Yu Z; Ma B; Zhou Y; Zhang M; Long H; Wang Y; Fan Q
    Cancer Invest; 2007; 25(7):535-41. PubMed ID: 17952746
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Superior anti-tumor protection and therapeutic efficacy of vaccination with allogeneic and semiallogeneic dendritic cell/tumor cell fusion hybrids for murine colon adenocarcinoma.
    Yasuda T; Kamigaki T; Kawasaki K; Nakamura T; Yamamoto M; Kanemitsu K; Takase S; Kuroda D; Kim Y; Ajiki T; Kuroda Y
    Cancer Immunol Immunother; 2007 Jul; 56(7):1025-36. PubMed ID: 17131118
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Allogeneic mRNA-based electrotransfection of autologous dendritic cells and specific antitumor effects against osteosarcoma in rats.
    Yu Z; Qian J; Wu J; Gao J; Zhang M
    Med Oncol; 2012 Dec; 29(5):3440-8. PubMed ID: 22843292
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Specific antitumor effects of tumor vaccine produced by autologous dendritic cells transfected with allogeneic osteosarcoma total RNA through electroporation in rats.
    Yu Z; Sun H; Zhang T; Yang T; Long H; Ma B
    Cancer Biol Ther; 2009 May; 8(10):973-80. PubMed ID: 19287216
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaccination of dendritic cells loaded with interleukin-12-secreting cancer cells augments in vivo antitumor immunity: characteristics of syngeneic and allogeneic antigen-presenting cell cancer hybrid cells.
    Suzuki T; Fukuhara T; Tanaka M; Nakamura A; Akiyama K; Sakakibara T; Koinuma D; Kikuchi T; Tazawa R; Maemondo M; Hagiwara K; Saijo Y; Nukiwa T
    Clin Cancer Res; 2005 Jan; 11(1):58-66. PubMed ID: 15671528
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fas-deficient fully allogeneic dendritic cells administered via an intratumoral injection route show efficient antitumor effects in murine models.
    Okano S; Kondoh H; Toshima T; Nakagawara H; Yoshizumi T; Soejima Y; Shirabe K; Harada M; Yoshikai Y; Maehara Y
    Fukuoka Igaku Zasshi; 2013 Jan; 104(1):15-26. PubMed ID: 23600321
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Engineered fusion hybrid vaccine of IL-18 gene-modified tumor cells and dendritic cells induces enhanced antitumor immunity.
    Xia D; Li F; Xiang J
    Cancer Biother Radiopharm; 2004 Jun; 19(3):322-30. PubMed ID: 15285878
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Allogeneic dendritic cell vaccine pulsed with heat shocked tumor cell lysate can enhance antitumor immunity].
    You J; Wang CL; Hao XS
    Zhonghua Yi Xue Za Zhi; 2007 Oct; 87(39):2785-90. PubMed ID: 18167273
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Syngeneic B16-F1 cells are more efficient than allogeneic Cloudman cells as antigen source in DC-based vaccination in the B16-F1 murine melanoma model.
    Mac Keon S; Bentivegna S; Levy EM; Marks MS; Mantegazza AR; Wainstok R; Mordoh J
    Vaccine; 2019 Aug; 37(35):4947-4955. PubMed ID: 31307876
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced tumor-specific long-term immunity of hemagglutinating [correction of hemaggluttinating] virus of Japan-mediated dendritic cell-tumor fused cell vaccination by coadministration with CpG oligodeoxynucleotides.
    Hiraoka K; Yamamoto S; Otsuru S; Nakai S; Tamai K; Morishita R; Ogihara T; Kaneda Y
    J Immunol; 2004 Oct; 173(7):4297-307. PubMed ID: 15383558
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Immunotherapeutic reactivity of dendritic cells loaded with a variety of antigen preparations].
    Shimizu K; Kuriyama H; Tamai H; Ueda Y; Yamagishi H; Shu S
    Gan To Kagaku Ryoho; 2004 Oct; 31(11):1637-9. PubMed ID: 15553668
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Specific antitumor effects of tumor vaccine produced by electrofusion between osteosarcoma cell and dendritic cell in rats.
    Yu Z; Fan Q; Hao X; Long H
    Cell Mol Immunol; 2004 Dec; 1(6):454-60. PubMed ID: 16293215
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sialic acid removal from dendritic cells improves antigen cross-presentation and boosts anti-tumor immune responses.
    Silva M; Silva Z; Marques G; Ferro T; Gonçalves M; Monteiro M; van Vliet SJ; Mohr E; Lino AC; Fernandes AR; Lima FA; van Kooyk Y; Matos T; Tadokoro CE; Videira PA
    Oncotarget; 2016 Jul; 7(27):41053-41066. PubMed ID: 27203391
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cell fusion between dendritic cells and whole tumor cells.
    Koido S; Gong J
    Methods Mol Biol; 2015; 1313():185-91. PubMed ID: 25947665
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influenza A infection enhances cross-priming of CD8+ T cells to cell-associated antigens in a TLR7- and type I IFN-dependent fashion.
    Wei J; Waithman J; Lata R; Mifsud NA; Cebon J; Kay T; Smyth MJ; Sadler AJ; Chen W
    J Immunol; 2010 Nov; 185(10):6013-22. PubMed ID: 20956347
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumour cell-dendritic cell fusion for cancer immunotherapy: comparison of therapeutic efficiency of polyethylen-glycol versus electro-fusion protocols.
    Lindner M; Schirrmacher V
    Eur J Clin Invest; 2002 Mar; 32(3):207-17. PubMed ID: 11895473
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor-dendritic cell fusion as a basis for cancer immunotherapy.
    Lee WT; Shimizu K; Kuriyama H; Tanaka H; Kjaergaard J; Shu S
    Otolaryngol Head Neck Surg; 2005 May; 132(5):755-64. PubMed ID: 15886631
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity of dendritic-tumor fusion hybrids and their utility in cancer immunotherapy.
    Shu S; Zheng R; Lee WT; Cohen PA
    Crit Rev Immunol; 2007; 27(5):463-83. PubMed ID: 18197808
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.